Clinical Trial

Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial

Study acronym: STEPS-BC
Recruiting
View on ClinicalTrials.gov →
Summary
This clinical trial studies whether a healthy living intervention (HLI), with or without a physical activity intervention (PAI), helps maintain the ability to exercise, heart health, and quality of life in breast cancer patients who are scheduled to receive chemotherapy treatment. Early detection and enhanced therapies for breast cancer have improved 5-year cancer-related survival rates. Unfortunately, many breast cancer survivors are at high risk for long-term exercise intolerance, decreased heart health, and lower quality of life following chemotherapy. Currently, there are no effective therapies to help patients maintain these areas throughout chemotherapy. The HLI in this study includes virtual health education classes, which provide useful information on topics like proper nutrition, managing stress, and sleep practices. This may help patients understand the importance of living a healthy lifestyle during chemotherapy. The PAI in this study consists of virtual exercise sessions personalized to the needs of the patient, which may make it easier for patients to stay active during chemotherapy. HLI with PAI may be a more effective way to help maintain ability to exercise, heart health, and quality of life in breast cancer patients who are scheduled to receive chemotherapy treatment.
Protocol Amendment History 4 changes
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-06-16
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-06-02
notable Primary completion pushed: 2029-09-01 -> 2030-04-30 2026-06-02
minor Completion pushed: 2030-01-31 -> 2030-04-30 2026-06-02
Trial Details
NCT Number NCT07474090
Lead Sponsor Wake Forest University Health Sciences
Conditions Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma, Breast Inflammatory Carcinoma, Locally Recurrent Breast Carcinoma
Enrollment 120 participants
Start Date 2026-05-27
Primary Completion 2030-04-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-15